Hippocrates AI, A generative AI company developing a large-scale language model focused on safety for healthcare has partnered with healthcare transformation company Eucalia to launch the first Japanese language Genai Healthcare Agent for clinical tasks for undiagnosed patients.
This partnership marks Hippocratic AI’s entry into the Japanese market.
Eucalia provides management and operational support to healthcare professionals, including optimizing healthcare, management and hospital operations.
To present this year, Japanese generative AI healthcare agents aim to support clinicians by employing time-consuming but non-critical patient-oriented tasks, including appointment scheduling, follow-up outreach, chronic care check-in, and medication adherence support.
Hippocratic AI aims to increase clinician workflow efficiency, enhance high-quality patient engagement, and improve patient outcomes.
“This partnership with Eucalia reflects our commitment to building not only multilingual but local fluent, clinically safe, culturally aligned generative AI agents,” said Munjal Shah, CEO and co-founder of Hippocrat AI, in a statement.
“Japan’s healthcare system is world class, but it’s tense. We believe our technology can significantly expand our capabilities without compromising quality or trust. Together with Eucalia, we are setting a new global benchmark on how generator AI can take responsibility for patient outcomes, strengthen clinical operations of scale, and support a more resilient healthcare system for Japanese people.”
Bigger trends
April, United Arab Emirates-based healthcare services providers Burjeel Holdings and Hippocratic AI have announced a strategic partnership to change healthcare delivery.
Through the Alliance, Hippocratic AI’s Genai Healthcare Agents were built for “non-diagnostic clinical tasks for patients” distributed to Burjeel Holdings healthcare facilities and physiotherapy clinics in the UAE and Oman.
By integrating the capabilities of Hippocratic AI, Burjeel Holdings was able to transform patient engagement and provide customized, sympathetic clinical conversations with patients.
In March, Hippocrates AI announced its appointment Seven new executives follow the end of the $141 million Series B round funding in January.
Medical executives who joined the company’s team include Dr. Chris Fan, Chief Commercial Officer of Pharma, Life Sciences and International Markets. Holly Vuglinovich, the provider’s chief growth officer. WB “Mitch” Mitchell, Chief Growth Officer of Government Division. Chitra Rakumanan, Vice President and General Manager of Payers. Eric Seastoll, vice president of international emerging markets.
January, Hippocrates AI $141 million closed The Series B round rated at $1.64 billion.
Kleiner PerkinsVC, which supported Amazon, Genentech and Google, led the round. Existing investors SV Angel, Premji, General Catalyst, A16Z, Nvidia, Universal Health Services and Wellspan Health also participated.
